← All trials
NCT05782192
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 13, 2019
- Primary completion
- Mar 25, 2022
- Completion date
- Mar 25, 2022
- First posted
- Mar 23, 2023
- Last posted
- Mar 23, 2023
- Enrollment
- 458
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shenzhen Salubris Pharmaceuticals Co., Ltd.Lead sponsor
- Sun Yat-Sen UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.